Recently, we disclosed the tryptophanol-derived oxazoloisoindolinone SLMP53-2 as a new p53-activating agent with in vitro and in vivo antitumor activity against hepatocellular carcinoma [19]. The gene discussed is TP53; the disease is hepatocellular carcinoma.